We are pleased to announce that Asphalion has been selected as a beneficiary of the 2025.1 edition of the ICEX Next Programme, an initiative by “ICEX España Exportación e Inversiones” designed to support the international growth of Spanish companies through expert advice and financial support.
At Asphalion, internationalization has always been part of our DNA. Today, we support pharmaceutical, biotechnology and medical device companies worldwide with regulatory, scientific and safety consulting services.
Within this edition of the programme, Asphalion is the only regulatory affairs company among the total group of beneficiary companies and ranks within the top 30. This further underlines our specialization and distinctive position in the life sciences sector.
The support provided through ICEX Next will help us strengthen our international expansion strategy, explore new opportunities and continue bringing our expertise to life sciences companies across global markets.
We would like to thank ICEX España Exportación e Inversiones for their confidence in our project. We look forward to this new stage with enthusiasm and a continued commitment to delivering excellence to our clients worldwide. More information: https://icexnext.es/
Asphalion is a beneficiary of the ICEX Next Programme, supported by ICEX España Exportación e Inversiones and co-financed by the European Union through the European Regional Development Fund (ERDF/FEDER).
For further information about our services: [email protected]
